Xenios said today it expanded its research & development and manufacturing operations to include a new combined facility.
The Reutlingen, Germany R&D and manufacturing facility was added as the company continues on what it calls an “aggressive growth strategy.”
“Given that no other company except Xenios is offering minimally invasive lung and heart therapies on 1 platform, and given that the Xenios platform provides fundamental advantages for patients with its minimally invasive lung and heart therapies, Xenios is growing rapidly. As a direct result of the recent significant cash infusion from existing investors led by Zukunftsfonds Heilbronn (ZFHN), which we announced in September, Xenios is able to enlarge its commercial operations per plan,” managing director Dr. Georg Matheis said in prepared remarks.
The new facilities are just over 30 miles south of its corporate headquarters in Heilbronn, Germany, the company said, in a region with a strong focus on medical device technology.
“We are focused on growing sales of our leading products in a highly profitable yet under-penetrated market. The Xenios strategy is to grow a highly profitable business in the U.S. and Europe with upside potential in Asia. Xenios is now generating significant revenues with a scalable business, direct sales in place in three EU countries, and global KOLs participating as product champions. The expansion of our manufacturing and R&D operations into a single facility near corporate headquarters is another big step in the successful execution of our growth strategy,” managing director Dr. Jürgen Böhm
Last week, Xenios said it won CE Mark approval in the European Union for its I-Cor synchronized cardiac assist device, touting it as the world’s 1st “heartbeat-synchronized” cardiac assist for cardiogenic shock and high-risk interventions.
Xenios, which claimed in September to have drummed up an 8-figure funding round, said the I-Cor system is designed to provide “beat-to-beat” cardiac assistance using a miniature pump “with synchronized pulses that are superimposed over the patient’s weakened heartbeats.”
